{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,27]],"date-time":"2026-02-27T23:05:47Z","timestamp":1772233547768,"version":"3.50.1"},"reference-count":17,"publisher":"BMJ","issue":"9","content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ Case Rep"],"accepted":{"date-parts":[[2020,8,24]]},"published-print":{"date-parts":[[2020,9]]},"abstract":"<jats:p>Chronic lymphatic leukaemia (CLL) is the most common leukaemia in the Western world. Ibrutinib, a tyrosine kinase inhibitor, is the treatment of choice on relapse or p53-dysfunction. Richter\u2019s transformation to diffuse large B cell lymphoma is most often seen. However, transformation to other aggressive lymphomas as plasmablastic lymphoma (PBL) does occur. PBL is an extremely aggressive lymphoma and is usually treated using a CHOP-like regimen (cyclophosphamide, doxorubicin, vincristine and prednisone\/dexamethasone), but with poor outcome. The only curative treatment is allogeneic stem cell transplant (ASCT).<\/jats:p>\n               <jats:p>We report on a case of CLL treated with ibrutinib that underwent transformation to PBL. Due to high expression of CD138, we added daratumumab to the chemotherapy with a good, but transitory response. The case did not make it to an ASCT. Targeting CD138 by daratumumab may be added to chemoimmune therapy for PBL.<\/jats:p>","DOI":"10.1136\/bcr-2020-235816","type":"journal-article","created":{"date-parts":[[2020,9,29]],"date-time":"2020-09-29T17:27:49Z","timestamp":1601400469000},"page":"e235816","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":16,"title":["Transformation to plasmablastic lymphoma in CLL upon ibrutinib treatment"],"prefix":"10.1136","volume":"13","author":[{"given":"Kristo","family":"Marvyin","sequence":"first","affiliation":[{"name":"Department of Haematology, Sykehuset \u00d8stfold HF, Gralum, \u00d8stfold, Norway"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eirik Brekka","family":"Tj\u00f8nnfjord","sequence":"additional","affiliation":[{"name":"Department of Haematology, Sykehuset \u00d8stfold HF, Gralum, \u00d8stfold, Norway"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Unni Mathilde","family":"Breland","sequence":"additional","affiliation":[{"name":"Department of Haematology, Sykehuset \u00d8stfold HF, Gralum, \u00d8stfold, Norway"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Geir Erland","family":"Tj\u00f8nnfjord","sequence":"additional","affiliation":[{"name":"Department of Haematology, Oslo Universitetssykehus, Oslo, Norway"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"239","published-online":{"date-parts":[[2020,9,29]]},"reference":[{"key":"2025082723120281000_13.9.e235816.1","doi-asserted-by":"publisher","DOI":"10.3322\/canjclin.57.1.43"},{"key":"2025082723120281000_13.9.e235816.2","doi-asserted-by":"crossref","first-page":"2056","DOI":"10.4045\/tidsskr.11.1349","article-title":"Chronic lymphocytic leukaemia in Norway--incidence and prognostic markers at diagnosis","volume":"132","author":"Tj\u00f8nnfjord","year":"2012","journal-title":"Tidsskr Nor Laegeforen"},{"key":"2025082723120281000_13.9.e235816.3","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(10)61381-5"},{"key":"2025082723120281000_13.9.e235816.4","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1215637"},{"key":"2025082723120281000_13.9.e235816.5","unstructured":"NCCN Continuing Education . NCCN Guidelines\u00ae Insights - Chronic Lymphocytic Leukemia\/Small Lymphocytic Lymphoma, Version 2, 2019. Available: https:\/\/education.nccn.org\/node\/84832 [Accessed 31 Jul 2020]."},{"key":"2025082723120281000_13.9.e235816.6","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1016\/j.canep.2019.04.002","article-title":"Richter syndrome epidemiology in a large population based chronic lymphocytic leukemia cohort from Norway","volume":"60","author":"Lenartova","year":"2019","journal-title":"Cancer Epidemiol"},{"key":"2025082723120281000_13.9.e235816.7","doi-asserted-by":"publisher","DOI":"10.1097\/PAS.0b013e31826cb1d1"},{"key":"2025082723120281000_13.9.e235816.8","doi-asserted-by":"publisher","DOI":"10.1034\/j.1600-0609.2001.00592.x"},{"key":"2025082723120281000_13.9.e235816.9","doi-asserted-by":"crossref","first-page":"2139","DOI":"10.1016\/j.humpath.2013.04.008","article-title":"Plasmablastic transformation of low-grade CD5+ B-cell lymphoproliferative disorder with Myc gene rearrangements","volume":"44","author":"Pan","year":"2013","journal-title":"Hum Pathol"},{"key":"2025082723120281000_13.9.e235816.10","doi-asserted-by":"crossref","first-page":"1413","DOI":"10.1182\/blood.V89.4.1413","article-title":"Plasmablastic lymphomas of the oral cavity: a new entity associated with the human immunodeficiency virus infection","volume":"89","author":"Delecluse","year":"1997","journal-title":"Blood"},{"key":"2025082723120281000_13.9.e235816.11","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2016-01-643569"},{"key":"2025082723120281000_13.9.e235816.12","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2014-10-567479"},{"key":"2025082723120281000_13.9.e235816.13","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2014-01-547737"},{"key":"2025082723120281000_13.9.e235816.14","doi-asserted-by":"publisher","DOI":"10.6004\/jnccn.2019.0002"},{"key":"2025082723120281000_13.9.e235816.15","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1001\/jamaoncol.2014.218","article-title":"Etiology of ibrutinib therapy discontinuation and outcomes in patients with chronic lymphocytic leukemia","volume":"1","author":"Maddocks","year":"2015","journal-title":"JAMA Oncol"},{"key":"2025082723120281000_13.9.e235816.16","doi-asserted-by":"crossref","DOI":"10.1182\/blood-2018-99-119112","article-title":"An immune based, Anti-CD138 targeting antibody for the treatment of multiple myeloma","volume":"132","author":"Yu","year":"2018","journal-title":"Blood"},{"key":"2025082723120281000_13.9.e235816.17","doi-asserted-by":"crossref","DOI":"10.2217\/ijh-2018-0010","article-title":"Current trends in the management of Richter's syndrome","volume":"7","author":"Allan","year":"2018","journal-title":"Int J Hematol Oncol"}],"container-title":["BMJ Case Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bcr-2020-235816","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,28]],"date-time":"2025-08-28T06:12:08Z","timestamp":1756361528000},"score":1,"resource":{"primary":{"URL":"https:\/\/casereports.bmj.com\/lookup\/doi\/10.1136\/bcr-2020-235816"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,9]]},"references-count":17,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2020,9,29]]},"published-print":{"date-parts":[[2020,9]]}},"alternative-id":["10.1136\/bcr-2020-235816"],"URL":"https:\/\/doi.org\/10.1136\/bcr-2020-235816","relation":{},"ISSN":["1757-790X"],"issn-type":[{"value":"1757-790X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,9]]}}}